Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.55 +0.04 (+0.08%)

Delayed Quote Updated: 3:09 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

July 08, 2024

From Genentech

Via Business Wire

3 Small-Cap Stocks With Explosive 2X Growth Potential ↗

July 08, 2024

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.

Via InvestorPlace

Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients ↗

July 05, 2024

Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung...

Via Benzinga

FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

July 05, 2024

From Genentech

Via Business Wire

Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

July 04, 2024

From Genentech

Via Business Wire

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗

June 27, 2024

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.

Via Benzinga

Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case ↗

June 24, 2024

The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for...

Via Benzinga

Topics Lawsuit

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗

June 21, 2024

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.

Via Benzinga

Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost ↗

June 21, 2024

How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.

Via InvestorPlace

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗

June 21, 2024

The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.

Via Benzinga

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche

June 19, 2024

The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors.

Via MarketBeat

Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 15, 2024

From Genentech

Via Business Wire

Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win ↗

June 11, 2024

An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.

Via Investor's Business Daily

Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗

June 07, 2024

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

Via Benzinga

Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk

June 07, 2024

From Genentech

Via Business Wire

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

June 11, 2024

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

Via FinancialNewsMedia

Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗

June 06, 2024

Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis.

Via Benzinga

2 Cathie Wood Biotech Stocks That Could Be Worth the Risk ↗

May 29, 2024

You don't need to buy her picks, but it's worth understanding them.

Via The Motley Fool

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

June 11, 2024

From FN Media Group LLC

Via GlobeNewswire

FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

May 29, 2024

From Genentech

Via Business Wire

If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today ↗

May 26, 2024

What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised.

Via The Motley Fool

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗

May 23, 2024

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

Via Benzinga

Topics Lawsuit

This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan ↗

May 21, 2024

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential.

Via Benzinga

FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

May 21, 2024

From Genentech

Via Business Wire

Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate ↗

May 16, 2024

Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with...

Via Benzinga

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

May 16, 2024

From Genentech

Via Business Wire

Can Ocugen Stock Keep Churning Higher? ↗

April 29, 2024

This tiny biotech caught fire in 2024. Can it sustain the momentum?

Via The Motley Fool

Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? ↗

April 24, 2024

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.